Pettus JH, D’Alessio D, Frias JP, et al. - In patients with type 2 diabetes (T2D) inadequately controlled on metformin, researchers tested the effectiveness and safety of RVT-1502, a novel oral glucagon receptor antagonist. For this investigation, T2D patients (n = 166) on a stable dose of metformin were randomized (1:1:1:1) to placebo or RVT-1502 5, 10, or 15 mg once daily for 12 weeks in phase 2, double-blind, randomized, placebo-controlled study. Over 12 weeks, RVT-1502 significantly decreased HbA_1c relative to placebo by 0.74%, 0.76%, and 1.05% in the 5-, 10-, and 15-mg groups, respectively, and fasting plasma glucose (FPG) reduced by 2.1, 2.2, and 2.6 mmol/L. Overall, the authors concluded that glucagon receptor antagonism with RVT-1502 significantly reduces HbA_1c and FPG, with a safety profile that encourages more clinical development through studies of longer duration.